6 results match your criteria: "Dell Medical School at Austin[Affiliation]"

Hemorrhagic Lacrimation and Epistaxis: Rare Findings in Acute Hemorrhagic Edema of Infancy.

Cutis

January 2023

Dr. Bambekova is from the University of Texas Health San Antonio, Long School of Medicine. Drs. Cervantes, Reichenberg, and Ruth are from the Department of Dermatology, Dell Medical School at Austin/Dell Children's Hospital, Austin, Texas.

View Article and Find Full Text PDF

A Fixed Drug Eruption to Medroxyprogesterone Acetate Injectable Suspension.

Cutis

March 2022

Dr. Patel is from the Long School of Medicine, University of Texas Health San Antonio. Drs. Cervantes, Keeling, and Adamson are from the Department of Internal Medicine, Division of Dermatology, Dell Medical School at Austin, Texas.

View Article and Find Full Text PDF

Importance: Hidradenitis suppurativa (HS) in pediatric patients has been understudied. Increased awareness and recognition of HS prevalence in children demand efforts to better understand this condition.

Objective: To describe the demographics, clinical features, treatment, associated comorbidities, and outcomes in a large cohort of pediatric patients with HS.

View Article and Find Full Text PDF

Successful treatment of recurrent advanced cutaneous squamous cell carcinoma with cemiplimab.

Dermatol Online J

October 2020

Division of Dermatology, Department of Internal Medicine, Dell Medical School at Austin, Austin, TX.

A 90-year-old man presented for evaluation of an incompletely excised squamous cell carcinoma above the right brow, with pathology demonstrating tumor extending to resection margins with perineural invasion. A cord of tumor was noted to extend past the orbital rim and towards the posterior orbit. Mohs excision versus coordinated resection and reconstruction with colleagues in the head and neck surgery and craniofacial plastic surgery departments were considered.

View Article and Find Full Text PDF
Article Synopsis
  • Atopic dermatitis (AD) is a chronic skin condition that often begins in childhood and can lead to other health issues, with dupilumab being the first biologic treatment approved for moderate to severe cases in adults and adolescents.
  • A study reviewed the off-label use of dupilumab in children, showing that 89.5% of patients accessed the medication after about 9 weeks, with varying dosing guidelines based on age.
  • The findings indicated that children generally tolerated dupilumab well, but optimal dosing for those under 12 years is still unclear, and the study faced limitations in data collection due to its retrospective nature.
View Article and Find Full Text PDF

Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.

Am J Psychiatry

April 2019

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, LoParo, Kinkead, Mletzko-Crowe, Mayberg, Craighead); Research Design Associates, Inc., Yorktown Heights, New York (Cole); Institute for Early Life Adversity Research, University of Texas Dell Medical School at Austin (Nemeroff); Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Mayberg); Department of Psychology, Emory University, Atlanta (Craighead).

Objective: Adults with major depressive disorder frequently do not achieve remission with an initial treatment. Addition of psychotherapy for patients who do not achieve remission with antidepressant medication alone can target residual symptoms and protect against recurrence, but the utility of adding antidepressant medication after nonremission with cognitive-behavioral therapy (CBT) has received little study. The authors aimed to evaluate the acute and long-term outcomes resulting from both sequences of combination treatments.

View Article and Find Full Text PDF